VIMGF (Vimian Group AB) Moat Score: 4/10 (As of Jun. 28, 2026)


VIMGF Vimian Group AB VIMGF
76 GF Score
Price $2.77
GF Value $3.26
! 2 Warning Signs
View Full Analysis

What is Vimian Group AB Moat Score?

Vimian Group AB VIMGF 76 Moat Score is 4 as of Jun. 28, 2026. GuruFocus rates VIMGF with a GF Score™ of 76/100 and a GF Value™ of $3.26. The stock has 2 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Vimian Group AB ranks better than 82.87% on this metric.

Vimian Group AB has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Vimian Group AB has Narrow Moat: Vimian Group AB has a modest position in the veterinary services market, with some valuable intellectual property and a growing distribution network. However, it faces competition that limits its pricing power and market share, resulting in a discernible but modest moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Vimian Group AB might have Narrow Moat - Discernible but modest moat.

Vimian Group AB  (OTCPK:VIMGF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Vimian Group AB Moat Score Related Terms

VIMGF vs TMO, DHR, IDXX: Moat Score Comparison

For the Diagnostics & Research subindustry, Vimian Group AB's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vimian Group AB Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's Moat Score distribution charts can be found below:

* The bar in red indicates where Vimian Group AB's Moat Score falls into.


VIMGF
76GF Score
Vimian Group AB VIMGF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Vimian Group AB (VIMGF) has a Moat Score of 4 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Vimian Group AB ranks #37 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 17.1%.
Is Vimian Group AB's Moat Score too high?
Vimian Group AB's current Moat Score is 4. Based on the distribution chart, Vimian Group AB ranks #37 out of 216 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vimian Group AB has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's Moat Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #37 out of 216 companies for Moat Score. This places Vimian Group AB in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Vimian Group AB's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current Moat Score of 4. The stock's GF Value™ is $3.26, compared to a current price of $2.77 — trading 15% below its estimated fair value. The current Moat Score is 4. Vimian Group AB's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current Moat Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vimian Group AB (VIMGF) Overvalued in 2026?

Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued. The current stock price of $2.77 is trading 15% below its estimated GF Value™ of $3.26.

Key valuation signals for VIMGF:

  • Moat Score: 4
  • GF Value™: $3.26 vs. price of $2.77 (15% below fair value)
  • GF Score™: 76/100 with 2 warning signs

No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vimian Group AB Business Description

Address Riddargatan 19, Stockholm, SWE, SE-11457
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
76GF Score

Get the complete analysis for VIMGF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.77
Price
$3.26
GF Value